David M Keeling

List of Publications by Year
in descending order

56 papers	5,007 citations	218677 26 h-index	182427 51 g-index
59 all docs	59 docs citations	59 times ranked	4853 citing authors

#	Article	IF	Citations
1	Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood, 2007, 109, 1870-1877.	1.4	646
2	Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 2012, 157, 47-58.	2.5	492
3	Guidelines on oral anticoagulation with warfarin â€“ fourth edition. British Journal of Haematology, 2011, 154, 311-324.	2.5	482
4	Clinical guidelines for testing for heritable thrombophilia. British Journal of Haematology, 2010, 149, 209-220.	2.5	434
5	The diagnosis and management of von <scp>W</scp>illebrand disease: a <scp>U</scp>nited <scp>K</scp>ingdom <scp>H</scp>aemophilia <scp>C</scp>entre <scp>D</scp>octors <scp>O</scp>rganization guideline approved by the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology. British Journal of Haematology, 2014, 167, 453-465.	2.5	297
6	The story of the discovery of heparin and warfarin. British Journal of Haematology, 2008, 141, 757-763.	2.5	274
7	The aspirin story â€“ from willow to wonder drug. British Journal of Haematology, 2017, 177, 674-683.	2.5	219
8	A practical guideline for the haematological management of major haemorrhage. British Journal of Haematology, 2015, 170, 788-803.	2.5	202
9	The management of heparin-induced thrombocytopenia. British Journal of Haematology, 2006, 133, 259-269.	2.5	184
10	Guidelines on the diagnosis and management of heparinâ€induced thrombocytopenia: second edition. British Journal of Haematology, 2012, 159, 528-540.	2.5	179
11	Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. British Journal of Haematology, 1998, 101, 483-486.	2.5	172
12	Periâ€operative management of anticoagulation and antiplatelet therapy. British Journal of Haematology, 2016, 175, 602-613.	2.5	159
13	Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. British Journal of Haematology, 2012, 159, 427-429.	2.5	148
14	Guideline on aspects of cancerâ€related venous thrombosis. British Journal of Haematology, 2015, 170, 640-648.	2.5	139
15	Guidelines on the investigation and management of venous thrombosis at unusual sites. British Journal of Haematology, 2012, 159, 28-38.	2.5	119
16	Relation between acute hypoxia and activation of coagulation in human beings. Lancet, The, 2003, 361, 2207-2208.	13.7	82
17	The diagnosis of deep vein thrombosis in symptomatic outpatients and the potential for clinical assessment and D-dimer assays to reduce the need for diagnostic imaging. British Journal of Haematology, 2004, 124, 15-25.	2.5	82
18	The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emergency Medicine Journal, 2014, 31, 163-168.	1.0	64

#	Article	IF	Citations
19	An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thrombosis and Haemostasis, 2006, 96, 630-41.	3.4	62
20	The management of heparin-induced thrombocytopenia. British Journal of Haematology, 2006, 135, 269-269.	2.5	59
21	Diagnosis and management of heritable thrombophilias. BMJ, The, 2014, 349, g4387-g4387.	6.0	45
22	Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery. British Journal of Ophthalmology, 2014, 98, 1320-1324.	3.9	42
23	Efficacy of Warfarin Reversal in Orthopedic Trauma Surgery Patients. Journal of Orthopaedic Trauma, 2007, 21, 26-30.	1.4	33
24	Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagulation and Fibrinolysis, 2004, 15, 503-504.	1.0	30
25	Nextâ€generation sequencing for the diagnosis ofMYH9â€RD: Predicting pathogenic variants. Human Mutation, 2020, 41, 277-290.	2.5	30
26	The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: coâ€segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. British Journal of Haematology, 2005, 128, 830-836.	2.5	28
27	Normal d-dimer levels do not exclude the diagnosis of cerebral venous sinus thrombosis. Journal of Neurology, 2002, 249, 1603-1604.	3.6	27
28	Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. British Journal of Haematology, 2006, 133, 331-336.	2.5	26
29	Patient selfâ€testing and selfâ€management of oral anticoagulation with vitamin <scp>K</scp> antagonists: guidance from the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology. British Journal of Haematology, 2014, 167, 600-607.	2.5	26
30	Von Willebrand disease, angiodysplasia and atorvastatin. British Journal of Haematology, 2010, 149, 159-160.	2.5	22
31	Activated prothrombin complex concentrate for the prevention of dabigatranâ€associated bleeding. British Journal of Haematology, 2014, 166, 152-153.	2.5	22
32	Idarucizumab for dabigatran overdose in a child. British Journal of Haematology, 2018, 180, 457-459.	2.5	22
33	The use of artificial neural network analysis can improve the riskâ€stratification of patients presenting with suspected deep vein thrombosis. British Journal of Haematology, 2019, 185, 289-296.	2.5	22
34	Combined oral contraceptives and the risk of myocardial infarction. Annals of Medicine, 2003, 35, 413-418.	3.8	21
35	A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B. British Journal of Haematology, 2005, 128, 885-885.	2.5	21
36	Duration of anticoagulation: decision making based on absolute risk. Blood Reviews, 2006, 20, 173-178.	5.7	19

#	Article	IF	Citations
37	The use of rituximab in two children with allo-antibodies towards factor VIII. British Journal of Haematology, 2006, 133, 214-216.	2.5	10
38	Effect of age on factor <scp>IX</scp> levels in symptomatic carriers of Haemophila B Leyden. British Journal of Haematology, 2015, 169, 448-449.	2.5	9
39	The use of age-dependent D-dimer cut-off values to exclude deep vein thrombosis. Reply to "Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded". Haematologica 2012;97(10):1507-13. Haematologica, 2012, 97, e43-e44.	3.5	8
40	Management of venous thromboembolism â€“ controversies and the future. British Journal of Haematology, 2013, 161, 755-763.	2.5	8
41	Controversies in venous thromboembolism â€” 2015. Blood Reviews, 2016, 30, 27-33.	5.7	8
42	Management of bleeding in patients taking <scp>FX</scp>a and <scp>FII</scp>a inhibitors. British Journal of Haematology, 2013, 160, 1-2.	2.5	6
43	â€˜Sagittal sinus thrombosis in a teenager: homocystinuria associated with reversible antithrombin deficiencyâ€™. Developmental Medicine and Child Neurology, 2002, 44, 498-498.	2.1	4
44	Thrombophilia screening or screaming. Journal of Thrombosis and Haemostasis, 2010, 8, 1191-1192.	3.8	4
45	How to interpret a prolonged prothrombin time or activated partial thromboplastin time. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, C10-C12.	0.5	4
46	Is there a benefit in computed tomography screening for cancer in patients with unprovoked proximal deep venous thrombosis? A cohort study in the Oxford University Hospitals <scp>NHS</scp> Trust. British Journal of Haematology, 2016, 172, 978-979.	2.5	3
47	Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism. Blood, 2016, 128, 139-139.	1.4	3
48	Venous thromboembolism: risk of recurrence and long-term anticoagulation. British Journal of Hospital Medicine (London, England: 2005), 2015, 76, 72-77.	0.5	2
49	Reducing the need for diagnostic imaging in suspected cases of deep vein thrombosis. British Journal of Haematology, 2019, 184, 682-684.	2.5	2
50	Laboratory monitoring of antiplatelet therapy. , 2001, , 386-406.		1
51	Stockings to prevent post-thrombotic syndromeâ€”where are we now?. Lancet Haematology,the, 2018, 5, e4-e5.	4.6	1
52	Management of an uncommon form of type 2M VWD: a single centre experience. The Journal of Haemophilia Practice, 2016, 3, 47-50.	0.4	1
53	Hormone replacement therapy, thrombosis and thrombophilia. The Journal of the British Menopause Society, 2005, 11, 74-75.	1.3	0
54	Authorsâ€™ response. British Journal of Ophthalmology, 2014, 98, 1136-1137.	3.9	0

#	Article	IF	Citations
55	Unexpected haemophilia despite pre-natal testing - a combined haemophilia A and haemophilia B family. British Journal of Haematology, 2017, 179, 182-182.	2.5	0
56	Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?. Blood, 2016, 128, 272-272.	1.4	0